Publications

This study uses gold-standard, quantitative MRI to establish normative benchmarks for changes in visceral fat, liver fat, muscle volume, and muscle fat infiltration that occur following real-world weight loss or weight gain in ~3,000 adults. These reference data, derived in the pre-incretin era from the UK Biobank, directly enable robust obesity clinical trial design: powering sample size calculations, defining placebo arm behaviour, and supporting label claims for emerging weight-loss therapies. 

MRCP+ predicts long-term event free survival in patients diagnosed with PSC.New qmAOM score with number of strictures, proportion of 3–5mm ducts and number of ducts with strictures or dilatations demonstrated strong prognostic value in event free survival

This review reframes obesity-related HFpEF as a multiorgan condition rather than a purely cardiac disease. It highlights how metabolic dysfunction and excess adiposity affect the heart and other organs, and summarises emerging evidence for incretin-based therapies and the role of multiorgan imaging in understanding disease mechanisms, monitoring disease progression and informing clinical trial design.

Stain variability materially affects automated fibrosis measurement, but ensemble collagen quantification with uncertainty mapping can make multi-centre digital pathology more reliable, interpretable and trustworthy.

Periductal cT1 (Pd-cT1) is a novel multiparametric MRI/MRCP method that quantifies liver tissue fibro-inflammation surrounding the bile ducts. This study demonstrated that Pd-cT1 detects periductal abnormalities in patients with large-duct PSC, and elevated values were associated with established risk markers and with subsequent adverse clinical outcomes. This supports the potential role of Pd-cT1 as an objective biomarker for monitoring disease activity in PSC. 

This work suggests potential for real-world clinical utility of LiverMultiScan alongside elastography in standard care for steatotic liver disease in primary care.

This work provides validation of the quality of the large-scale data using CMR in CoverScan, such that it was included in meta-analysis instigated by other academic cardiology groups.

Editorial accompanying Windell et al. (2025) highlights spatially resolved AI in histopathology: preserving tissue context better matches pathologist interpretation and supports biologically coherent disease-activity assessment.

The ALERT score has been developed as a simple screening tool using routine blood tests (ALT, triglycerides) and diabetes status to identify people with high liver fat content (≥8%). It outperformed existing clinical scores and VCTE-CAP, offering a practical, high-specificity tool to help clinicians find patients suitable for MASLD/MASH trials and those at increased risk of liver complications, especially in type 2 diabetes. Available at: https://mashscan.com/#calculators 

An AI system detected portal tracts and quantified spatial steatosis and inflammation in liver biopsies, aligned with manual scoring, and showed higher inflammatory burden in AIH than MASLD/MASH, enabling spatial automated assessment.

Clinical utility of MRCP+ in predicting transplant-free survival in patients with PSC.Total number of strictures and proportion of 3–5mm ducts demonstrated strong performance in forecasting PSC-related transplant,with stable accuracy over a 10-year period

Clinical utility of MRCP+ and a proposed pathway for integration into the management of PSC was explored.Hepatologists had strong interest and trust MRCP+ for diagnosis and monitoring.Pricing of £500 was unlikely to hinder its adoption in clinical practic.

A systematic review and meta-analysis of 19 studies including 1040 patient data have shown that cT1 and liver fat content (LFC) are significantly more reliable in detecting change in liver health in people living with MASLD-MASH, compared to liver stiffness NITs. Liver stiffness measurements are less suited to monitoring individual patients.